Trials / Unknown
UnknownNCT05118841
Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors
A Phase 1, Open-Label, First in Human, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZX-4081 in Patients With Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Nanjing Zenshine Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 1, first-in-human, open-label, multicenter, dose escalation and dose expansion study to investigate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor activity of ZX-4081 administered orally (PO) twice daily (BID) in 28-day cycles in patients with Advanced Solid Tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZX-4081 | Twice daily (BID), oral dosing of ZX-4081 at the assigned dose level in a 28-day cycle |
Timeline
- Start date
- 2022-01-03
- Primary completion
- 2023-05-01
- Completion
- 2024-05-01
- First posted
- 2021-11-12
- Last updated
- 2022-02-02
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05118841. Inclusion in this directory is not an endorsement.